© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
X4 Pharmaceuticals, Inc. (XFOR) stock declined over -3.61%, trading at $0.49 on NASDAQ, down from the previous close of $0.51. The stock opened at $0.50, fluctuating between $0.47 and $0.53 in the recent session.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Employees | 127 |
Beta | 0.39 |
Sales or Revenue | $0.00 |
5Y Sales Change% | -1% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) stock price is $0.49 in the last trading session. During the trading session, XFOR stock reached the peak price of $0.53 while $0.47 was the lowest point it dropped to. The percentage change in XFOR stock occurred in the recent session was -3.61% while the dollar amount for the price change in XFOR stock was -$0.02.
The NASDAQ listed XFOR is part of Biotechnology industry that operates in the broader Healthcare sector. X4 Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Robert David Arbeit
Senior Vice President of Clinical Devel. and Translational Research
Dr. Keith T. Flaherty M.D.
Founder & Member of Corporation Advisory Board
Mr. Mark Baldry M.B.A.
Chief Commercial Officer
Dr. Mary DiBiase Ph.D.
Chief Operating Officer
Dr. Richard Peters M.D., Ph.D.
Founder
Dr. Murray W. Stewart M.D.
Interim Chief Medical Officer & Director
Dr. Renato T. Skerlj Ph.D.
Founder
Dr. Arthur Taveras Ph.D.
Chief Scientific Officer
Mr. Adam S. Mostafa
Managing Director
Dr. Paula Ragan Ph.D.
Chief Executive Officer, Pres & Director
XFOR's closing price is 87.47% higher than its 52-week low of $0.26 where as its distance from 52-week high of $1.60 is -69.42%.
Number of XFOR employees currently stands at 127.
Official Website of XFOR is: https://www.x4pharma.com
XFOR could be contacted at phone 857 529 8300 and can also be accessed through its website. XFOR operates from 61 North Beacon Street, Boston, MA 02134, United States.
XFOR stock volume for the day was 1.69M shares. The average number of XFOR shares traded daily for last 3 months was 3.79M.
The market value of XFOR currently stands at $83.45M with its latest stock price at $0.49 and 170.55M of its shares outstanding.